...
首页> 外文期刊>Cardiovascular Drugs and Therapy >Mitochondria and GSK-3β in Cardioprotection Against Ischemia/Reperfusion Injury
【24h】

Mitochondria and GSK-3β in Cardioprotection Against Ischemia/Reperfusion Injury

机译:线粒体和GSK-3β对缺血/再灌注损伤的心脏保护作用

获取原文
获取原文并翻译 | 示例
           

摘要

The mitochondrion is a powerhouse of the cell, a platform of cell signaling and decision-maker of cell death, including death by ischemia/reperfusion. Ischemia shuts off ATP production by mitochondria, and cell viability is compromised by energy deficiency and build-up of cytotoxic metabolites during ischemia. Furthermore, the mitochondrial permeability transition pore (mPTP) is primed by ischemia to open upon reperfusion, leading to reperfusion-induced cell necrosis. mPTP opening can be suppressed by ischemic preconditioning (IPC) and other interventions that induce phosphorylation of GSK-3β. Activation of the mitochondrial ATP-sensitive K+ channel (mKATP channel) is an important signaling step in a trigger phase of IPC, which ultimately enhances GSK-3β phosphorylation upon reperfusion, and this channel functions as a mediator of cytoprotection as well. The mitochondrial Ca2+-activated K+ channel appears to play roles similar to those of the mKATP channel, though regulatory mechanisms of the channels are different. Phosphorylated GSK-3β inhibits mPTP opening presumably by multiple mechanisms, including preservation of hexokinase II in mPTP complex, prevention of interaction of cyclophilin-D with adenine nucleotide translocase, inhibition of p53 activation and attenuation of ATP hydrolysis during ischemia. However, cytoprotective signaling pathways to GSK-3β phosphorylation and other mPTP regulatory factors are modified by co-morbidities, including type 2 diabetes, and such modification makes the myocardium refractory to IPC and other cardioprotective agents. Regulatory mechanisms of mPTP, and their alterations by morbidities frequently associated with ischemic heart disease need to be further characterized for translation of mitochondrial and mPTP biology to the clinical arena.
机译:线粒体是细胞的强大动力,是细胞信号传导的平台,是细胞死亡(包括缺血/再灌注死亡)的决策者。缺血会阻断线粒体的ATP产生,并且在缺血期间能量缺乏和细胞毒性代谢产物的积累会损害细胞活力。此外,线粒体通透性转换孔(mPTP)由局部缺血致使在再灌注时开放,从而导致再灌注诱导的细胞坏死。可通过缺血预处理(IPC)和其他诱导GSK-3β磷酸化的干预措施来抑制mPTP的开放。线粒体ATP敏感的K + 通道(mK ATP 通道)的激活是IPC触发阶段的重要信号转导步骤,最终在再灌注时增强GSK-3β磷酸化,并且此通道也充当细胞保护的介质。线粒体Ca 2 + 激活的K + 通道似乎起着与mK ATP 通道相似的作用,尽管该通道的调节机制是不同的。磷酸化的GSK-3β可能通过多种机制抑制mPTP的开放,包括在mPTP复合物中保留己糖激酶II,防止亲环蛋白D与腺嘌呤核苷酸转运酶的相互作用,抑制p53活化和缺血期间ATP水解的减弱。但是,GSK-3β磷酸化和其他mPTP调节因子的细胞保护信号通路被包括2型糖尿病在内的合并症所修饰,这种修饰使心肌对IPC和其他心脏保护剂具有耐药性。为了将线粒体和mPTP生物学翻译到临床领域,需要进一步表征mPTP的调节机制及其因经常与缺血性心脏病相关的发病率而发生的改变。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号